David Chan, MD | Redondo Beach, CA

Dr. David Chan, M.D.

Claim this profile

Torrance Memorial Physician Network / Cancer Care

Studies Breast Cancer
Studies Pancreatic Cancer
16 reported clinical trials
28 drugs studied

Area of expertise

1Breast Cancer
David Chan, M.D. has run 8 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage II
2Pancreatic Cancer
David Chan, M.D. has run 2 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative

Affiliated Hospitals

Image of trial facility.
Torrance Memorial Physician Network / Cancer Care
Image of trial facility.
CS Cancer At The Hunt Cancer Center

Clinical Trials David Chan, M.D. is currently running

Image of trial facility.

Tart Cherry + Fish Oil

for Joint Pain

Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia. There is preliminary evidence in mouse models that when given together, these supplements may have an even greater anti-inflammatory effect than when taken separately14. Although to our knowledge, no human studies have tested this hypothesis. This study has been designed to test the hypothesis that Tart Cherry and fish oil when given in combination over a 12-week period could produce beneficial changes in joint function when compared to Tart Cherry or fish oil in isolation in an obese breast cancer population experiencing AIMSS. Secondary outcomes to be assessed include pain, functional performance, quality of life and cognition.
Recruiting1 award Phase < 18 criteria
Image of trial facility.

Cisplatin

for Oropharyngeal Cancer

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.
Recruiting1 award Phase 27 criteria

More about David Chan, M.D.

Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments David Chan, M.D. has experience with
  • Placebo
  • Anastrozole
  • Abemaciclib
  • Imlunestrant
  • Tamoxifen
  • Letrozole

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does David Chan, M.D. specialize in?
Is David Chan, M.D. currently recruiting for clinical trials?
Are there any treatments that David Chan, M.D. has studied deeply?
What is the best way to schedule an appointment with David Chan, M.D.?
What is the office address of David Chan, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security